Molecular Diagnostics Market Trends, Size and Landscape Outlook By 2030

Molecular Diagnostics Industry Overview

The global molecular diagnostics market size was valued at USD 37.04 billion in 2021 and is expected to decline at a compound annual growth rate (CAGR) of -1.6% from 2022 to 2030.

The shrinking of the market can be attributed to the decline in demand for molecular COVID-19 testing during the forecast period. However, factors such as technological advancements, rising elderly population, and increasing demand for genetic testing is boosting the growth of the market. In addition, rising demand for PoC testing can be attributed to increasing demand for self-testing diagnostics, and patient awareness about faster diagnostics.

The outbreak of COVID-19 impelled the diagnostics industry into action, with a race to develop novel and rapid diagnostics kits for the detection of coronavirus. The pandemic led to a spike in the revenue of companies operating in the infectious diseases segment. For instance, in April 2021, a 59% rise in revenue was reported by Thermo Fisher Scientific, owing to the diagnostics division that delivered 150% growth. However, with the rising number of vaccinations globally, the demand for diagnostics for COVID-19 testing is likely to decline during the forecast period.

Gather more insights about the market drivers, restrains and growth of the Global Molecular Diagnostics Market

U.S. molecular diagnostics market size, by product, 2020 - 2030 (USD Million)

The rising geriatric population globally is increasing the risk of getting numerous diseases including cancer, cardiovascular diseases, obesity, neurological disorders, and diabetes. According to a UN report, in 2020, there were about 727 million people aged 65 years & above globally. In addition, the number of individuals aged 80 and above is projected to double by 2050, that is, to cross more than 1.5 billion. The fact that the global geriatric population is expected to grow over the forecast period is anticipated to be a high-impact rendering driver of the market.

The geriatric population is more likely to suffer from COVID-19 due to decreased immune function, multimorbidity, and physiological changes associated with aging. According to WHO Regional Director for Europe, till April 2020, around 95% of the deaths were reported among patients 60 years or above. Furthermore, more than 50% of deaths occurred in patients aged 80 years or older.

In addition, the growing incidence of infectious diseases is expected to propel market growth over the forecast period. Moreover, the growing incidence of STIs, such as HIV and HPV, is expected to expand the target population, thereby boosting the market growth. According to WHO, globally, in 2020, the prevalence and incidence of HIV were approximately 37.7 million and 1.5 million, respectively. Furthermore, people suffering from HIV are highly susceptible to other infections such as tuberculosis, which is the leading cause of death among HIV-affected people.

The rising initiatives by market players to improve access to cost-effective resources are anticipated to drive the molecular diagnostics market growth. Molecular diagnostics render accurate & effective results and has indispensable applications in disease diagnostics. However, high prices associated with molecular tests are one of the major factors impeding this market.

Browse through Grand View Research’s Clinical Diagnostics Industry Research Reports.

  • Polymerase Chain Reaction MarketThe global polymerase chain reaction market size was valued at USD 23.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 0.9% from 2021 to 2028.
  • DNA Sequencing Market The global DNA sequencing market size was valued at USD 4.7 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 11.4% from 2020 to 2027.

Market Share Insights

  • May 2021: Roche acquired GenMark Diagnostics for USD 1.8 billion. This acquisition will help Roche expand its molecular diagnostics portfolio.
  • December 2021: The company also completed the acquisition of TIB Molbiol Group. TIB Molbiol Group has around 45 CE-IVD approved assays for the diagnosis of infectious diseases, inherited genetic testing, transplant medicine, and hematology testing.

Key Companies profiled:

Some prominent players in the global molecular diagnostics market include

  • BD
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Abbott
  • Agilent Technologies, Inc.
  • Danaher
  • Hologic Inc. (Gen Probe)
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Grifols, S.A.
  • Hoffmann-La Roche, Ltd.
  • Siemens Healthineers AG
  • Sysmex Corporation

Order a free sample PDF of the Molecular Diagnostics Market Intelligence Study, published by Grand View Research.

Comments are closed